Literature DB >> 18647321

Allergenicity, immunogenicity and dose-relationship of three intact allergen vaccines and four allergoid vaccines for subcutaneous grass pollen immunotherapy.

H Henmar1, G Lund, L Lund, A Petersen, P A Würtzen.   

Abstract

Different vaccines containing intact allergens or chemically modified allergoids as active ingredients are commercially available for specific immunotherapy. Allergoids are claimed to have decreased allergenicity without loss of immunogenicity and this is stated to allow administration of high allergoid doses. We compared the allergenicity and immunogenicity of four commercially available chemically modified grass pollen allergoid products with three commercially available intact grass pollen allergen vaccines. The allergenicity was investigated with immunoglobulin (Ig)E-inhibition and basophil activation assays. Human T cell proliferation and specific IgG-titres following mouse immunizations were used to address immunogenicity. Furthermore, intact allergen vaccines with different contents of active ingredients were selected to study the influence of the allergen dose. In general, a lower allergenicity for allergen vaccines was clearly linked to a reduced immunogenicity. Compared with the vaccine with the highest amount of intact allergen, the allergoids caused reduced basophil activation as well as diminished immunogenicity demonstrated by reduced T cell activation and/or reduced induction of murine grass-specific IgG antibodies. Interestingly, intact allergen vaccines with lower content of active ingredient exhibited similarly reduced allergenicity, while immunogenicity was still higher or equal to that of allergoids. The low allergenicity observed for some allergoids was inherently linked to a significantly lower immunogenic response questioning the rationale behind the chemical modification into allergoids. In addition, the linkage between allergenicity, immunogenicity and dose found for intact allergen vaccines and the immunogen as well as allergenic immune responses observed for allergoids suggest that the modified allergen vaccines do not contain high doses of immunologically active ingredients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18647321      PMCID: PMC2527365          DOI: 10.1111/j.1365-2249.2008.03710.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  Identification of isoform-specific T-cell epitopes in the major timothy grass pollen allergen, Phl p 5.

Authors:  P A Würtzen; A Bufe; M Wissenbach; H O Madsen; H Ipsen; J Arnved; R J Van Neerven
Journal:  Clin Exp Allergy       Date:  1999-12       Impact factor: 5.018

2.  Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid.

Authors:  C J Corrigan; J Kettner; C Doemer; O Cromwell; A Narkus
Journal:  Allergy       Date:  2005-06       Impact factor: 13.146

3.  Responses of human birch pollen allergen-reactive T cells to chemically modified allergens (allergoids).

Authors:  D Dormann; C Ebner; E R Jarman; E Montermann; D Kraft; A B Reske-Kunz
Journal:  Clin Exp Allergy       Date:  1998-11       Impact factor: 5.018

Review 4.  Flow-assisted allergy diagnosis: current applications and future perspectives.

Authors:  D G Ebo; J Sainte-Laudy; C H Bridts; C H Mertens; M M Hagendorens; A J Schuerwegh; L S De Clerck; W J Stevens
Journal:  Allergy       Date:  2006-09       Impact factor: 13.146

5.  Studies on "allergoids" prepared from naturally occurring allergens. I. Assay of allergenicity and antigenicity of formalinized rye group I component.

Authors:  D G Marsh; L M Lichtenstein; D H Campbell
Journal:  Immunology       Date:  1970-05       Impact factor: 7.397

6.  Studies on allergoids from naturally occurring allergens. III. Preparation of ragweed pollen allergoids by aldehyde modification in two steps.

Authors:  D G Marsh; P S Norman; M Roebber; L M Lichtenstein
Journal:  J Allergy Clin Immunol       Date:  1981-12       Impact factor: 10.793

7.  T-cell epitopes of Phl p 1, major pollen allergen of timothy grass (Phleum pratense): evidence for crossreacting and non-crossreacting T-cell epitopes within grass group I allergens.

Authors:  S Schenk; H Breiteneder; M Susani; N Najafian; S Laffer; M Duchêne; R Valenta; G Fischer; O Scheiner; D Kraft
Journal:  J Allergy Clin Immunol       Date:  1995-12       Impact factor: 10.793

8.  Analysis of human T cell clones reactive with group V grass pollen allergens.

Authors:  W D Müller; T Karamfilov; B Fahlbusch; H Vogelsang; L Jäger
Journal:  Int Arch Allergy Immunol       Date:  1994-12       Impact factor: 2.749

9.  Recognition of T cell epitopes and lymphokine secretion by rye grass allergen Lolium perenne I-specific human T cell clones.

Authors:  H L Spiegelberg; L Beck; D D Stevenson; G Y Ishioka
Journal:  J Immunol       Date:  1994-05-01       Impact factor: 5.422

10.  Measurement of basophil-activating capacity of grass pollen allergens, allergoids and hypoallergenic recombinant derivatives by flow cytometry using anti-CD203c.

Authors:  H Kahlert; O Cromwell; H Fiebig
Journal:  Clin Exp Allergy       Date:  2003-09       Impact factor: 5.018

View more
  12 in total

1.  Reduced in vitro T-cell responses induced by glutaraldehyde-modified allergen extracts are caused mainly by retarded internalization of dendritic cells.

Authors:  Bärbel Heydenreich; Iris Bellinghausen; Steffen Lorenz; Helene Henmar; Dennis Strand; Peter A Würtzen; Joachim Saloga
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

Review 2.  Utility and Comparative Efficacy of Recombinant Allergens Versus Allergen Extract.

Authors:  Hardik D Patel; Jeffrey M Chambliss; Meera R Gupta
Journal:  Curr Allergy Asthma Rep       Date:  2017-08-18       Impact factor: 4.806

3.  Direct contact between dendritic cells and bronchial epithelial cells inhibits T cell recall responses towards mite and pollen allergen extracts in vitro.

Authors:  D Papazian; V R Wagtmann; S Hansen; P A Würtzen
Journal:  Clin Exp Immunol       Date:  2015-06-11       Impact factor: 4.330

4.  Nitration of the egg-allergen ovalbumin enhances protein allergenicity but reduces the risk for oral sensitization in a murine model of food allergy.

Authors:  Eva Untersmayr; Susanne C Diesner; Gertie Janneke Oostingh; Kathrin Selzle; Tobias Pfaller; Cornelia Schultz; Yingyi Zhang; Durga Krishnamurthy; Philipp Starkl; Regina Knittelfelder; Elisabeth Förster-Waldl; Arnold Pollak; Otto Scheiner; Ulrich Pöschl; Erika Jensen-Jarolim; Albert Duschl
Journal:  PLoS One       Date:  2010-12-02       Impact factor: 3.240

5.  Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination.

Authors:  Susanne Vrtala; Monika Fohr; Raffaela Campana; Christian Baumgartner; Peter Valent; Rudolf Valenta
Journal:  Vaccine       Date:  2011-01-05       Impact factor: 3.641

6.  A novel and well tolerated mite allergoid subcutaneous immunotherapy: evidence of clinical and immunologic efficacy.

Authors:  Albert Roger; Nathalie Depreux; Yani Jurgens; Matthew D Heath; Gloria Garcia; Murray A Skinner
Journal:  Immun Inflamm Dis       Date:  2014-05-29

Review 7.  Nanomaterials in the Context of Type 2 Immune Responses-Fears and Potentials.

Authors:  Martin Himly; Robert Mills-Goodlet; Mark Geppert; Albert Duschl
Journal:  Front Immunol       Date:  2017-04-25       Impact factor: 7.561

8.  Molecular fingerprinting of complex grass allergoids: size assessments reveal new insights in epitope repertoires and functional capacities.

Authors:  S Starchenka; A J Bell; J Mwange; M A Skinner; M D Heath
Journal:  World Allergy Organ J       Date:  2017-04-24       Impact factor: 4.084

Review 9.  Novel strategies in immunotherapy for allergic diseases.

Authors:  Mohana Rajakulendran; Elizabeth Huiwen Tham; Jian Yi Soh; H P Van Bever
Journal:  Asia Pac Allergy       Date:  2018-04-09

Review 10.  Epicutaneous Immunotherapy for Aeroallergen and Food Allergy.

Authors:  Gabriela Senti; Seraina von Moos; Thomas M Kündig
Journal:  Curr Treat Options Allergy       Date:  2013-12-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.